-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47

Benzinga·11/10/2026 14:59:11
Listen to the news
Wells Fargo analyst Derek Archila maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $45 to $47.